1st Quarter - Report

CVS HEALTH (AND SUBSIDIARIES) for CVS HEALTH (AND SUBSIDIARIES)

Firm
Client
Income
—
Expenses
$3,210,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to drug pricing transparency, women's health, and COVID-19 testing, vaccination and treatment. H.R. 1770, The Equitable Community Access to Pharmacist Services Act S. 2477, The Equitable Community Access to Pharmacist Services Act

LobbyistCovered position, as disclosed
ROBERT BUTORA —
KAITLYN LANE —
YUJIN LEE —
JOY MCGLAUN —
SHANNON PENBERTHY —
AMY ROSENBAUM —
ROBERT TANNER WARBINTON —

Contacted: SENATE; White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 2477 (118th), H.R. 1770 (118th)

Taxation/Internal Revenue Code TAX

Issues related to the corporate tax rate.

LobbyistCovered position, as disclosed
SHANNON PENBERTHY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Insurance INS

Issues related to employer, small group and individual insurance markets. H.R. 6283 - Delinking Revenue from Unfair Gouging Act

LobbyistCovered position, as disclosed
ROBERT BUTORA —
KAITLYN LANE —
YUJIN LEE —
JOY MCGLAUN —
SHANNON PENBERTHY —
AMY ROSENBAUM —
ROBERT TANNER WARBINTON —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6283 (118th)

Labor Issues/Antitrust/Workplace LBR

Issues related to the competitive nature of the pharmacy benefit manager industry and workforce issues.

LobbyistCovered position, as disclosed
ROBERT BUTORA —
KAITLYN LANE —
YUJIN LEE —
JOY MCGLAUN —
SHANNON PENBERTHY —
AMY ROSENBAUM —
MELISSA SCHULMAN —
ROBERT TANNER WARBINTON —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Consumer Issues/Safety/Products CSP

Issues related to organized retail crime and consumer safety.

LobbyistCovered position, as disclosed
JOY MCGLAUN —
SHANNON PENBERTHY —
ROBERT TANNER WARBINTON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Issues related to Medicare Part D, Medicare Advantage, Medicaid, mental health, and telehealth. Issues related to COVID testing, vaccination, and treatment. Issues related to Accountable Care Organizations. Issues related to Medicare Shared Savings Program. S. 1339 - Pharmacy Benefit Manager Reform Act of 2023 S. 1967 - Patients Before Middlemen Act of 2023 S. 2973 - Modernizing and Ensuring PBM Accountability (MEPA) Act S. 3430 - Better Mental Health Care, Lower-Cost Drugs, and Extenders Act H.R. 2679 - Pharmacy Benefit Manager Accountability Act of 2023 H.R. 3285 - Fairness for Patient Medications Act H.R. 1613 - Drug Price Transparency in Medicaid Act of 2023 H.R. 3561 - Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 H.R. 5378 - Lower Costs, More Transparency Act H.R. 2880 - Protecting Patients Against PBM Abuses Act

LobbyistCovered position, as disclosed
NICOLE BURDA —
ROBERT BUTORA —
KAITLYN LANE —
YUJIN LEE —
JOY MCGLAUN —
SHANNON PENBERTHY —
AMY ROSENBAUM —
MELISSA SCHULMAN —
ROBERT TANNER WARBINTON —

Contacted: White House Office; SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: S. 2973 (118th), S. 1967 (118th), S. 3430 (118th), H.R. 2679 (118th), H.R. 2880 (118th), H.R. 5378 (118th), S. 1339 (118th), H.R. 3285 (118th), H.R. 3561 (118th), H.R. 1613 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.